Who are Alpha 1-Antitrypsin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): alpha-1-Proteinase Inhibitor, Alpha1-Proteinase Inhibitor, Aralast NP, Alpha-1 antitrypsin (AAT), NRL972, PF-07321332 Dose 5.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alpha-1-antitrypsin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Alpha 1-Antitrypsin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alpha 1-Antitrypsin (Alpha 1-Antitrypsin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor; protein replacement therapy. Area: Pulmonology; Genetic/Metabolic Disorders.

marketed Protease inhibitor; protein replacement therapy Neutrophil elastase Pulmonology; Genetic/Metabolic Disorders Small molecule Live · refreshed every 30 min

Target snapshot

Alpha 1-Antitrypsin (Alpha 1-Antitrypsin) — University of Minnesota. Alpha 1-antitrypsin is a protease inhibitor that replaces deficient or dysfunctional alpha 1-antitrypsin protein to prevent neutrophil elastase-mediated tissue destruction in the lungs.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Alpha 1-Antitrypsin TARGET	Alpha 1-Antitrypsin	University of Minnesota	marketed	Protease inhibitor; protein replacement therapy	Neutrophil elastase
alpha-1-Proteinase Inhibitor	alpha-1-Proteinase Inhibitor	Institute for Human Genetics and Biochemistry	marketed	Protease inhibitor / Enzyme replacement therapy	Neutrophil elastase
Alpha1-Proteinase Inhibitor	Alpha1-Proteinase Inhibitor	Baxalta now part of Shire	marketed	Protease inhibitor (protein replacement therapy)	Neutrophil elastase (indirect target via AAT inhibition)
Aralast NP	Aralast NP	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Protease inhibitor (augmentation therapy)	Alpha-1 protease inhibitor (AAT); neutrophil elastase inhibition
Alpha-1 antitrypsin (AAT)	Alpha-1 antitrypsin (AAT)	CSL Behring	phase 3	Protease inhibitor / Protein replacement therapy	Neutrophil elastase
NRL972	NRL972	Norgine	phase 3	Neutrophil elastase inhibitor	Neutrophil elastase (NE)
PF-07321332 Dose 5	pf-07321332-dose-5	Pfizer	marketed	Protease inhibitor	Main protease (MPro) of SARS-CoV-2	Pending regulatory approval

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor; protein replacement therapy class)

University of Minnesota · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alpha 1-Antitrypsin — Competitive Intelligence Brief. https://druglandscape.com/ci/alpha-1-antitrypsin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing